---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027733"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:48:51.203959+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q4 net loss $0.45/sh; cash $781M; Phase 3 ReDiscover-2 trial mid-2025

## Summary
- Net loss of $76.0M ($0.45/sh) in Q4 2024 vs $83.5M ($0.67/sh) in Q4 2023.
- Cash, cash equivalents and investments of $781.3M at Dec 31, 2024, expected to fund operations into H2 2027.
- Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in PI3Kα-mutated breast cancer to initiate mid-2025; 540 patients, PFS primary endpoint.
- Phase 1b data showed 11.4-month median PFS and 39% ORR in 2L patients with PI3Kα-mutated HR+/HER2- advanced breast cancer.
- Full year 2024 revenue $10.0M (down from $25.5M); net loss $337.7M ($2.36/sh).

## SEC filing metadata
- accession: 0000950170-25-027733
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017025027733/0000950170-25-027733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017025027733/rlay-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027733
- JSON: https://secwatch.observer/filing/0000950170-25-027733.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.